Parallax Volatility Advisers, L.P. Revance Therapeutics, Inc. Call Options Transaction History

Parallax Volatility Advisers, L.P.

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2023 Aug 14, 2023	SELL	$24.7 - $37.61 $182,780 - $278,314	-7,400 Reduced 42.53%	10,000 $253,000
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $319,464 - $613,698	17,400 New	17,400 $560,000
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $459,993 - $913,887	32,100 Added 116.3%	59,700 $1.61 Million
Q2 2022 Aug 15, 2022	BUY	$11.52 - $20.4 $317,952 - $563,040	27,600 New	27,600 $381,000
Q1 2019 May 15, 2019	SELL	$15.4 - $20.39 $277,200 - $367,020	-18,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$27.45 - $33.35 $494,100 - $600,300	18,000 New	18,000 $494,000

234

82.8M

680K

896K

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

Get notified when there are updates to the investment portfolio of Parallax Volatility Advisers, L.P., based on Form 13F filings with the SEC.

Stay updated on Parallax Volatility Advisers, L.P. with notifications on news.